AIDS research and therapy · 2025
Factors associated with interrupted pre-exposure prophylaxis (PrEP) in a Brazilian cohort: a brief communication.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pinheiro Patricia Matias, Lima Nathalia Pedrosa, Miranda Angelica Espinosa, Costa Filho Valbert Oliveira, Fiuza Romeiro Igor Pacheco, Rocha Hermano Alexandre Lima, de Araújo Wildo Navegantes
Аннотация
OBJECTIVE: To analyze factors associated with the discontinuation of pre-exposure prophylaxis (PrEP) for HIV among users in Brazil.
METHODS: An analytical case-control study was conducted using retrospective data (2018-2020) from PrEP users monitored by Brazil's Unified Health System (SUS) via the Medicines Logistics Control System (SICLOM). Cases (interrupted PrEP, n = 629) were matched 1:10 by sex at birth and age to controls (maintained PrEP, n = 6290). Logistic regression identified factors associated with discontinuation.
RESULTS: Factors significantly associated with PrEP discontinuation included previous anal lesions (adjusted Odds Ratio: 1.92; 95% Confidence Interval [CI]: 1.06-3.28; p = 0.022), active infections within the first 30 days of PrEP (aOR: 1.51; 95% CI 1.07-2.07; p = 0.014), and frequent medication forgetfulness (aOR: 1.48; 95% CI 1.19-1.84; p < 0.001). Not experiencing adverse effects during the first month was protective (aOR: 0.73; 95% CI 0.61-0.87; p < 0.001). The median time until discontinuation was 8 months.
CONCLUSION: Early clinical experiences and adherence behaviors are critical for PrEP continuation. Enhanced support and monitoring, particularly in the first 30 days post-initiation, are pivotal to improve PrEP persistence in Brazil.
METHODS: An analytical case-control study was conducted using retrospective data (2018-2020) from PrEP users monitored by Brazil's Unified Health System (SUS) via the Medicines Logistics Control System (SICLOM). Cases (interrupted PrEP, n = 629) were matched 1:10 by sex at birth and age to controls (maintained PrEP, n = 6290). Logistic regression identified factors associated with discontinuation.
RESULTS: Factors significantly associated with PrEP discontinuation included previous anal lesions (adjusted Odds Ratio: 1.92; 95% Confidence Interval [CI]: 1.06-3.28; p = 0.022), active infections within the first 30 days of PrEP (aOR: 1.51; 95% CI 1.07-2.07; p = 0.014), and frequent medication forgetfulness (aOR: 1.48; 95% CI 1.19-1.84; p < 0.001). Not experiencing adverse effects during the first month was protective (aOR: 0.73; 95% CI 0.61-0.87; p < 0.001). The median time until discontinuation was 8 months.
CONCLUSION: Early clinical experiences and adherence behaviors are critical for PrEP continuation. Enhanced support and monitoring, particularly in the first 30 days post-initiation, are pivotal to improve PrEP persistence in Brazil.